ReposiTrak Balansräkning Hälsa
Finansiell hälsa kriterier kontrolleras 6/6
ReposiTrak har ett totalt eget kapital på $50.5M och en total skuld på $0.0 vilket ger sin skuldsättningsgrad till 0%. Dess totala tillgångar och totala skulder är $57.4M respektive $6.9M. ReposiTrak s EBIT är $7.5M vilket gör dess räntetäckningsgrad -5.4. Den har kontanter och kortsiktiga investeringar på $26.4M.
Viktig information
0%
Skuldsättning i förhållande till eget kapital
US$0
Skuld
| Räntetäckningsgrad | -5.4x |
| Kontanter | US$26.41m |
| Eget kapital | US$50.49m |
| Summa skulder | US$6.88m |
| Totala tillgångar | US$57.38m |
Nya uppdateringar om finansiell hälsa
Recent updates
TRAK: Expanding Food Traceability Adoption And Compliance Wins Will Drive Upside
Analysts have kept their ReposiTrak price target effectively unchanged at approximately $16.00, reflecting only very small tweaks in inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the stock. What's in the News A wholesale grocery cooperative in the Southern United States became the first wholesaler to reach full supplier to store traceability using ReposiTrak’s Touchless Traceability solution, achieving FSMA 204 compliance without case-level scanning or changes to distribution center workflows (Key Developments).TRAK: Expanding Traceability Network Adoption Will Support Future Upside
Analysts held ReposiTrak's fair value estimate at $16.00 per share while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the stock's risk and earnings profile. What's in the News ReposiTrak reported that eighteen fresh fruit and vegetable companies have joined the queue for the ReposiTrak Traceability Network to prepare for FDA Key Data Element sharing across their supply chains, covering a wide range of growers and distributors across the United States (Key Developments).TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have maintained their $16.00 price target on ReposiTrak, linking this steady view to only slight adjustments in discount rate and future P/E assumptions rather than any change in projected growth or profitability. What's in the News ReposiTrak and SPAR Group, Inc.TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have reaffirmed a $16.00 price target for ReposiTrak, citing only minimal tweaks to underlying assumptions such as discount rate, revenue growth, profit margin and future P/E, which together leave their overall valuation view effectively unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability is reported as the first to achieve end to end traceability under FDA FSMA Section 204, with hundreds of thousands of Key Data Element records generated across shipments, and several more corporate customers nearing similar go live milestones (Key Developments).TRAK: Expanding Traceability Network And Share Buybacks Will Support Future Upside
Analysts have modestly reduced their price target on ReposiTrak to reflect a slightly lower future P/E assumption of 36.44x, while keeping key fair value and growth inputs broadly unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability has achieved end to end FSMA 204 traceability, generating hundreds of thousands of FDA Key Data Element records without case level scanning, with three more corporate customers close to similar go live points (Key Developments).TRAK: Traceability Network Adoption Will Support Higher Future Profitability
Analysts have reduced their price target on ReposiTrak from $29 to $16, citing updated assumptions in their models for slower revenue growth, a lower future P/E multiple, and a higher profit margin profile. What's in the News ReposiTrak reported completing a share repurchase program announced on May 9, 2019, buying back a total of 2,220,026 shares, or 11.63% of the company, for US$14.46 million, including 79,927 shares, or 0.44%, repurchased between October 1, 2025 and December 31, 2025 for US$1.1 million (Key Developments).ReposiTrak: Better Business, Fairer Price, Still Not A Buy
Summary ReposiTrak, Inc. is a micro-cap SaaS firm focused on supply chain compliance, food safety, and traceability for retailers and suppliers. TRAK's revenue grew 10% YoY, driven by recurring subscriptions and expanding services to existing customers, especially as retailer requirements outpace federal mandates. Operating expenses rose 3%, but revenue outpaced costs, supporting a 28% increase in operating income and strong revenue-per-employee metrics. Liquidity remains robust with $28.8M in cash and zero debt, though higher tax rates and rising costs warrant close monitoring if adoption slows. Read the full article on Seeking AlphaInvestors Will Want ReposiTrak's (NYSE:TRAK) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Subdued Growth No Barrier To ReposiTrak, Inc.'s (NYSE:TRAK) Price
ReposiTrak, Inc.'s ( NYSE:TRAK ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong sell...ReposiTrak's (NYSE:TRAK) Performance Is Even Better Than Its Earnings Suggest
ReposiTrak, Inc. ( NYSE:TRAK ) just reported healthy earnings but the stock price didn't move much. Investors are...Earnings Not Telling The Story For ReposiTrak, Inc. (NYSE:TRAK)
With a price-to-earnings (or "P/E") ratio of 62.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...ReposiTrak, Inc. (NYSE:TRAK) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 71.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...
Critical Focus On Traceability Solutions Powers Revenue Growth And Profitability Surge
Emphasis on enhancing traceability solutions and strategic revenue focus predicts significant growth, with aims to improve net margins and year-over-year growth.Track And Trace, But Don't Race: Why ReposiTrak Might Be Overvalued
Summary ReposiTrak shows solid growth potential with traceability services and recurring revenue but is currently overvalued with a high P/E ratio of 62.09x. Despite strong financials and profitability, rising operational expenses and heavy FDA dependency pose significant risks. Expansion into adjacent markets and AI-driven operational efficiencies are promising, but traceability revenue remains a small portion of the business. Given the speculative nature and high valuation, I recommend holding off on investing in ReposiTrak at this price. Read the full article on Seeking AlphaReposiTrak, Inc.'s (NYSE:TRAK) P/E Is Still On The Mark Following 28% Share Price Bounce
ReposiTrak, Inc. ( NYSE:TRAK ) shareholders have had their patience rewarded with a 28% share price jump in the last...ReposiTrak (NYSE:TRAK) Has More To Do To Multiply In Value Going Forward
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...Why Investors Shouldn't Be Surprised By ReposiTrak, Inc.'s (NYSE:TRAK) 28% Share Price Surge
Despite an already strong run, ReposiTrak, Inc. ( NYSE:TRAK ) shares have been powering on, with a gain of 28% in the...Analys av finansiell ställning
Kortfristiga skulder: TRAK s kortfristiga tillgångar ( $33.1M ) överstiger dess kortfristiga skulder ( $6.8M ).
Långfristiga skulder: TRAK s kortfristiga tillgångar ( $33.1M ) överstiger dess långfristiga skulder ( $114.9K ).
Skuld till eget kapital Historik och analys
Skuldnivå: TRAK är skuldfri.
Minska skulden: TRAK har inga skulder jämfört med för 5 år sedan när dess skuldsättningsgrad var 13.4%.
Skuldtäckning: TRAK har ingen skuld, därför behöver den inte täckas av operativt kassaflöde.
Räntetäckning: TRAK har inga skulder, därför är täckning av räntebetalningar inget problem.
Balansräkning
Upptäck friska företag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/25 16:45 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/06/30 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
ReposiTrak, Inc. bevakas av 4 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Thomas Forte | D.A. Davidson & Co. |
| Ananda Baruah | Loop Capital Markets |
| Thomas Forte | Maxim Group |